biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Revolution Medicines projects
6 ClinicalTrials.gov programs sponsored by Revolution Medicines.
Revolution Medicines has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)
Revolution Medicines
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
RMC-6236
Revolution Medicines
Pancreatic Cancer
1 trial -
RMC-6236-301
Revolution Medicines
non-small cell lung cancer
1 trial -
RMC-6236-302
Revolution Medicines
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
daraxonrasib
Revolution Medicines
NSCLC (Non-small Cell Lung Cancer)
1 trial -
daraxonrasib
Revolution Medicines
Pancreatic Cancer
2 trials
Frequently asked questions
How many clinical projects does Revolution Medicines have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.